

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known:

10/540993

Application Number	
Filing Date	June 28, 2005
First Named Inventor	K. Dolezal et al.
Art Unit	
Examiner Name	
Attorney Docket Number	J507-005 US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Traviss Mcintosh III/ (04/01/2007)
-----------------------	-------------------------------------

Date Considered	04/01/2007
-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JC17 Rec'd PCT/PTO 28 JUN 2005

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/540993
		Filing Date	June 28, 2005
		First Named Inventor	K. Dolezal et al.
		Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	J507-005 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/TM/		DUTTA, S.P., et al., "Synthesis and Biological Activities of Some N-(Nitro-Aminobenzyl) Adenosines", Journal of Medicinal Chemistry, American Chemical Society, Washington, US vol. 18, no. 8 1975	
/TM/		BRESSI, J C, et al., "Adenosine Analogues As Inhibitors of Trypanosoma Brucei Phosphoglycerate Kinase: Elucidation of a Novel Binding Mode for A 2-Amino-N6-Substituted Adenosine", Journal Of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 43, no. 22, 2000	
/TM/		FLEYSHER M.H., et al., "Synthesis and Biological Activity of Some New N6-Substituted Purine Nucleosides", J. Med. Chem., vol. 12, 1969, pages 1056-1061	
/TM/		WANNER, M J, et al., "2-Netro Analogues of Adenosine and 1-Deazaadenosine: Synthesis and Binding Studies at the Adenosine A1, A2A and A3 Receptor Subtypes", Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, no. 18, September 2000 (2000-09)	
/TM/		TRIVEDI, B K, et al., "C2N6-Disubstituted Adenosines: Synthesis and Structure-Activity Relationships", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 32, 1989, pages 1667-1673	
/TM/		MAGYAR-TABORI, K., et al., "High in Vitro Shoot Proliferation in the Apple Cultivar Jonagold induced by Benzyladenine Analogues", ACTA Agronomica Hungarica, vol. 50, 2002, pages 191-195	

Examiner Signature	/Traviss McIntosh III/ (04/01/2007)	Date Considered	04/01/2007
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.